'More Is Not Better' in Metastatic Castration|Resistant Prostate Cancer

'More Is Not Better' in Metastatic Castration-Resistant Prostate Cancer

CHICAGO-Combination therapy with enzalutamide, abiraterone, and prednisone did not prolong overall survival in men with metastatic ...

More Is Not Better in Metastatic CR Prostate Cancer - Medscape

CHICAGO — More is not better when it comes to inhibition of the androgen receptor in men with metastatic castration-resistant prostate ...

Comparing Sequencing of Abiraterone and Enzalutamide in Men ...

Background: There are no validated clinical decision tools to aid optimal treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC) ...

Perspectives on Treatment of Metastatic Castration-Resistant ...

More than 80% of patients have bone metastases at castration-resistant prostate cancer (CRPC) diagnosis [6]. The process by which prostate cancer cells become ...

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

therapy (ADT) or hormone therapy may no longer work completely to stop prostate cancer from growing, most men with mCRPC remain on ADT because some prostate.

Treatments for castration-resistant prostate cancer

It can also be called hormone-refractory or hormone-resistant prostate cancer. Non-metastatic castration-resistant prostate cancer has not spread to other parts ...

Castration-Resistant Prostate Cancer: What to Know - WebMD

There is no cure, but new treatments may help you live longer. CRPC can be metastatic or nonmetastatic. Metastatic CRPC. This is when the ...

Real-world overall survival with abiraterone acetate versus ... - Nature

To obtain the best ... Prostate cancer (PC) is the most common cancer ... metastatic castration-resistant prostate cancer: the Prostate Cancer ...

Metastatic Castration-Resistant Prostate Cancer Remains ...

Early use of more intensive therapies targeting androgen receptor and other oncogenic drivers in treatment-naïve primary prostate cancer (PC) ...

Abiraterone or Enzalutamide for Patients With Metastatic Castration ...

Importance Abiraterone acetate and enzalutamide are recommended as preferred treatments for metastatic castration-resistant prostate cancer ( ...

Metastatic Castration-Resistant Prostate Cancer: Advances in ...

Metastatic PC generally responds to initial androgen deprivation therapy. However, most patients will inevitably develop treatment resistance ...

Abiraterone and Olaparib for Metastatic Castration ... - NEJM Evidence

FACT-P scores range from 0 to 156, with higher scores indicating better HRQoL for men with prostate cancer (full definitions are provided in the ...

Metastatic prostate cancer remains incurable, why? - ScienceDirect

Androgen deprivation therapy is given as the most effective initial treatment to patients. However, after the initial response, almost all patients will ...

Evolving patterns of metastatic castration‐resistant prostate cancer

2, 3, 9-11 With availability of better treatments for mCRPC, patients are living longer and have more therapeutic options. In addition, the ...

A Report From the First Global Prostate Cancer Consensus ...

For most symptomatic patients with mCRPC who did not receive docetaxel or abiraterone in the castration-sensitive or castration-naive setting, 71.08% of the ...

Treatments for metastatic castration-sensitive prostate cancer

Metastatic prostate cancer is prostate cancer that has spread to other parts of the body. The goal of treatment is to help you live longer and try to improve ...

Diagnosed With Metastatic Castration-Resistant Prostate Cancer

With metastatic castration-resistant prostate cancer (mCRPC), or hormone-refractory prostate cancer, your current therapy is no longer ...

Treatment Considerations in Metastatic Castration-Resistant ...

Many of these agents are also life prolonging for men with mCRPC, but the optimal timing and sequencing of the available therapies is not known.

Real-world treatment patterns and overall survival among men with ...

Real-world treatment patterns and survival in metastatic castration-resistant prostate cancer (mCRPC) have not been characterized for the ...

Xtandi Approved for High-Risk Prostate Cancer - NCI

From castration-resistant to castration-sensitive localized prostate cancer · Better metastasis-free survival, time with no treatment · Side ...